IntegriChain Acquires Blue Fin Group

Endpoint Clinical Acquires Bluefin

September 14, 2026

Software

Endpoint Clinical acquired Bluefin, a Boston-based provider of clinical supply forecasting and planning technology. The acquisition expands Endpoint into clinical supply planning, with Bluefin continuing to operate independently and remain compatible with RTSM systems across the industry.

Warburg Pincus Acquires Integrace Private Limited

July 15, 2026

Pharmaceuticals

Warburg Pincus acquired 100% of Integrace Private Limited, a domestic orthopedics and gynecology-focused pharmaceutical formulations company, leading to full exits for existing shareholders True North Fund VI LLP and Temasek (via V-Science Investments). Industry veteran Rehan Khan was appointed CEO to lead Integrace’s next phase of growth as part of Warburg Pincus’ therapy-focused platform strategy.

IntegriChain Acquires Federal Compliance Solutions

July 9, 2024

Healthcare Services

IntegriChain has acquired Federal Compliance Solutions (FCS), a life‑sciences advisory and managed‑services firm focused on government pricing, contracting, and gross‑to‑net. The deal expands IntegriChain’s outsourcing and advisory capabilities, bringing FCS’s team of more than 60 professionals into IntegriChain’s ~750‑person global organization to deepen contracts & pricing and gross‑to‑net offerings for pharmaceutical manufacturers.

IntegriChain Acquires BridgeView Data Solutions

June 18, 2024

Data & Analytics

IntegriChain has acquired the commercial data warehouse and data aggregation assets (DataBridge) of BridgeView Life Sciences LLC, integrating BridgeView's AI-assisted data exploration and field intelligence into IntegriChain’s ICyte platform. The deal expands IntegriChain's commercial data capabilities for pharmaceutical manufacturers and is the company's sixth acquisition and first since partnering with private equity backer Nordic Capital.

Nordic Capital Acquires Majority Stake in IntegriChain from Accel-KKR

November 8, 2023

Cloud & SaaS

Nordic Capital has agreed to acquire a majority share in IntegriChain, a Philadelphia-based provider of a data-driven commercialization and market-access platform for the pharmaceutical industry, from Accel-KKR. The terms were not disclosed; closing is expected before year-end and is subject to customary regulatory and closing conditions.

IntegriChain Acquires Cumberland's Life Sciences Division

April 13, 2020

Healthcare Services

IntegriChain has acquired the Life Sciences Division of Cumberland, adding the division's employees and assets to its data and managed services platform for market access, contracts, pricing and revenue management. The deal expands IntegriChain's customer base to more than 220 life sciences manufacturers (including 20 of the top 20) and grows the combined team to over 350 professionals; Lincoln International arranged debt financing and Clearsight Advisors advised Cumberland on the sale.